Brightman DS, et al. - In patients with Temple syndrome (an imprinting disorder), researchers ascertained if treatment with growth hormone improves growth outcomes. Medical records of 14 Temple syndrome patients, 7 of whom were treated with growth hormone, were analyzed. The results obtained from the retrospective observational study indicate that the height standard deviation score (SDS) increased a median of 1.31 SDS with a median increased height velocity of 5.30 cm/year after 1 year of growth hormone treatment. These outcomes suggest short-term height SDS improvement with growth hormone treatment similar to the response in subjects treated under the small for gestational age indication. In all patients with Temple syndrome with short stature, they recommend considering growth hormone therapy.